Antitumor efficacy of 34.5ENVE: A transcriptionally retargeted and vstat120-expressing oncolytic virus

Ji Young Yoo; Amy Haseley; Anna Bratasz; E. Antonio Chiocca; Jianying Zhang; Kimerly Powell; Balveen Kaur

doi:10.1038/mt.2011.208

Antitumor efficacy of 34.5ENVE: A transcriptionally retargeted and vstat120-expressing oncolytic virus

Ji Young Yoo, Amy Haseley, Anna Bratasz, E. Antonio Chiocca, Jianying Zhang, Kimerly Powell, Balveen Kaur

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

Here, we describe the construction and testing of a novel herpes simplex virus type 1 (HSV-1) derived oncolytic virus (OV): 34.5ENVE (viral ICP34.5 Expressed by Nestin promotor and Vstat120 Expressing), for the treatment of cancer. This virus showed significant glioma-specific killing and antiangiogenic effects in vitro and in vivo. Treatment of subcutaneous and intracranial glioma-bearing mice with 34.5ENVE showed a significant increase in median survival of mice in four different glioma models. Histology and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) revealed reduced microvessel density (MVD) and increased tumoral necrosis in 34.5ENVE-treated tumor tissue compared to control OV-treated tumor tissue. Collectively, these results describe the construction, efficacy, and impact on tumor microenvironment of a transcriptionally driven OV armed with Vstat120 gene expression. These preclinical results will facilitate future clinical testing of 34.5ENVE.

Original language	English (US)
Pages (from-to)	287-297
Number of pages	11
Journal	Molecular Therapy
Volume	20
Issue number	2
DOIs	https://doi.org/10.1038/mt.2011.208
State	Published - Feb 2012
Externally published	Yes

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Genetics
Pharmacology
Drug Discovery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/mt.2011.208

Cite this

@article{bc9c7b34d9b04bcab892564daff59586,

title = "Antitumor efficacy of 34.5ENVE: A transcriptionally retargeted and vstat120-expressing oncolytic virus",

abstract = "Here, we describe the construction and testing of a novel herpes simplex virus type 1 (HSV-1) derived oncolytic virus (OV): 34.5ENVE (viral ICP34.5 Expressed by Nestin promotor and Vstat120 Expressing), for the treatment of cancer. This virus showed significant glioma-specific killing and antiangiogenic effects in vitro and in vivo. Treatment of subcutaneous and intracranial glioma-bearing mice with 34.5ENVE showed a significant increase in median survival of mice in four different glioma models. Histology and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) revealed reduced microvessel density (MVD) and increased tumoral necrosis in 34.5ENVE-treated tumor tissue compared to control OV-treated tumor tissue. Collectively, these results describe the construction, efficacy, and impact on tumor microenvironment of a transcriptionally driven OV armed with Vstat120 gene expression. These preclinical results will facilitate future clinical testing of 34.5ENVE.",

author = "Yoo, {Ji Young} and Amy Haseley and Anna Bratasz and Chiocca, {E. Antonio} and Jianying Zhang and Kimerly Powell and Balveen Kaur",

note = "Funding Information: This work was supported by funding from the National Institutes of Health grant (1R01NS064607, and 1R01CA150153 to B.K.; NS045758 to C.B.) and the National Research Foundation of Korea Grant funded by the Korean Government (NRF-2009-352-E00035 to J.Y.Y).",

year = "2012",

month = feb,

doi = "10.1038/mt.2011.208",

language = "English (US)",

volume = "20",

pages = "287--297",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Antitumor efficacy of 34.5ENVE

T2 - A transcriptionally retargeted and vstat120-expressing oncolytic virus

AU - Yoo, Ji Young

AU - Haseley, Amy

AU - Bratasz, Anna

AU - Chiocca, E. Antonio

AU - Zhang, Jianying

AU - Powell, Kimerly

AU - Kaur, Balveen

N1 - Funding Information: This work was supported by funding from the National Institutes of Health grant (1R01NS064607, and 1R01CA150153 to B.K.; NS045758 to C.B.) and the National Research Foundation of Korea Grant funded by the Korean Government (NRF-2009-352-E00035 to J.Y.Y).

PY - 2012/2

Y1 - 2012/2

N2 - Here, we describe the construction and testing of a novel herpes simplex virus type 1 (HSV-1) derived oncolytic virus (OV): 34.5ENVE (viral ICP34.5 Expressed by Nestin promotor and Vstat120 Expressing), for the treatment of cancer. This virus showed significant glioma-specific killing and antiangiogenic effects in vitro and in vivo. Treatment of subcutaneous and intracranial glioma-bearing mice with 34.5ENVE showed a significant increase in median survival of mice in four different glioma models. Histology and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) revealed reduced microvessel density (MVD) and increased tumoral necrosis in 34.5ENVE-treated tumor tissue compared to control OV-treated tumor tissue. Collectively, these results describe the construction, efficacy, and impact on tumor microenvironment of a transcriptionally driven OV armed with Vstat120 gene expression. These preclinical results will facilitate future clinical testing of 34.5ENVE.

AB - Here, we describe the construction and testing of a novel herpes simplex virus type 1 (HSV-1) derived oncolytic virus (OV): 34.5ENVE (viral ICP34.5 Expressed by Nestin promotor and Vstat120 Expressing), for the treatment of cancer. This virus showed significant glioma-specific killing and antiangiogenic effects in vitro and in vivo. Treatment of subcutaneous and intracranial glioma-bearing mice with 34.5ENVE showed a significant increase in median survival of mice in four different glioma models. Histology and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) revealed reduced microvessel density (MVD) and increased tumoral necrosis in 34.5ENVE-treated tumor tissue compared to control OV-treated tumor tissue. Collectively, these results describe the construction, efficacy, and impact on tumor microenvironment of a transcriptionally driven OV armed with Vstat120 gene expression. These preclinical results will facilitate future clinical testing of 34.5ENVE.

UR - http://www.scopus.com/inward/record.url?scp=84863011273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863011273&partnerID=8YFLogxK

U2 - 10.1038/mt.2011.208

DO - 10.1038/mt.2011.208

M3 - Article

C2 - 22031239

AN - SCOPUS:84863011273

SN - 1525-0016

VL - 20

SP - 287

EP - 297

JO - Molecular Therapy

JF - Molecular Therapy

IS - 2

ER -

Antitumor efficacy of 34.5ENVE: A transcriptionally retargeted and vstat120-expressing oncolytic virus

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this